Prognosis of stage 3 cancer
Pro Research Analysisby 
Searched over 200M research papers
Analyzed relevant papers
Prognosis of Stage 3 Cancer: Survival Rates and Key Prognostic Factors
Survival Outcomes in Stage 3 Cancers
Stage 3 cancer, regardless of type, generally indicates advanced local disease with regional lymph node involvement but no distant metastasis. Prognosis varies widely depending on the cancer type, patient characteristics, and specific tumor features.
- For stage III non-small cell lung cancer (NSCLC), median overall survival ranges from 9 to 34 months. Survival is generally higher in younger women, those with adenocarcinoma, good performance status, and stage IIIA disease. Improvements in treatment and staging have contributed to better outcomes in recent years, but the disease remains highly heterogeneous in prognosis .
- In stage III melanoma, 5-year overall survival is about 63%. Patients with nodal micrometastases have better outcomes (67% 5-year survival) compared to those with macrometastases (43%). Survival rates can range from 23% to 87% at 5 years, depending on factors like number of affected lymph nodes, tumor thickness, age, ulceration, and mitotic rate Balch2010Garbe2020.
- For stage III colon cancer, prognosis is influenced by a range of clinical, pathological, and molecular factors. Newer tools, such as pathomics signatures and circulating tumor DNA (ctDNA), are improving the ability to predict outcomes and tailor treatment Jiang2024Derangère2022Taieb2021+3 MORE.
Prognostic Factors in Stage 3 Lung Cancer
- Tumor size and nodal involvement are key predictors of survival in stage III NSCLC. Larger tumor volume, greater nodal volume, and presence of pleural effusion are associated with worse outcomes. Some radiomic features and tumor characteristics remain inconclusive as prognostic markers .
- Advances in chemotherapy, radiation, and surgical techniques have improved survival, but the prognosis remains variable due to the heterogeneity of stage III disease Casal-Mouriño2020Van Laar2020.
Prognostic Factors in Stage 3 Melanoma
- The number of tumor-containing lymph nodes, primary tumor thickness, patient age, ulceration, and anatomic site are independent predictors of survival. The mitotic rate of the primary tumor is also a strong prognostic factor .
- Survival rates for stage III melanoma are less favorable in real-world cohorts compared to some published data, especially for substages IIIA and IIIB .
Prognostic Factors in Stage 3 Colon Cancer
- Traditional TNM staging is being supplemented by new biomarkers and digital pathology tools. A pathomics signature based on digital slide analysis can independently predict disease-free and overall survival, and help identify patients most likely to benefit from chemotherapy .
- High expression of CDX2 and strong immune infiltration (CD3) are associated with particularly good prognosis in stage III colon cancer, and may help guide decisions about chemotherapy de-escalation .
- Circulating tumor DNA (ctDNA) detected after surgery is an independent negative prognostic marker for disease-free and overall survival. Patients with positive ctDNA have a higher risk of recurrence and worse outcomes .
- The presence and number of tumor deposits (TDs) in addition to lymph node metastases are negative prognostic factors. Combining TDs with lymph node count improves prognostic accuracy and may better stratify patients for treatment Cohen2021Ting2024.
- Molecular markers (such as microsatellite instability, BRAF, and KRAS mutations) and immune infiltration are increasingly recognized as important for prognosis and treatment selection .
Conclusion
The prognosis of stage 3 cancer is highly variable and depends on cancer type, patient characteristics, and specific tumor features. In lung, melanoma, and colon cancers, survival rates and risk of recurrence are influenced by tumor burden, nodal involvement, molecular markers, and emerging digital and liquid biopsy tools. Ongoing research is refining prognostic models to better personalize treatment and improve outcomes for patients with stage 3 cancer Casal-Mouriño2020Balch2010Garbe2020+7 MORE.
Sources and full results
Most relevant research papers on this topic
1
Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
Stage III lung cancer has a median survival of 9 to 34 months, with higher survival rates observed in younger Caucasian women with good performance status, adenocarcinoma, mutations, stage IIIA, and multidisciplinary-team-based diagnoses.
Highly Cited
2020·
139citations
·Ana Casal-Mouriño et al.PDF
4
Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: a systematic review and meta-analysis.
Stage III non-small cell lung cancer patients with chemoradiation show improved overall survival when tumor-size and nodal-size-related factors are considered.
Meta-Analysis
2020·
39citations
·Myra van Laar et al.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·
DOI
PDF
9
Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy
Prognostic markers like molecular signatures and immune infiltration can help tailor adjuvant treatment in stage III colon cancer, reducing over-treatment and reducing toxicity.
Highly Cited
2017·
88citations
·É. Auclin et al.PDF
10
Negative prognostic impact of tumor deposits in stage III colorectal cancer patients
The presence of tumor deposits is a negative prognostic factor in stage III colorectal cancer patients, with the co-existence of TDs and lymph node metastasis being the most detrimental.
Observational Study
2024·
2citations
·Ting Ma et al.PDF